Glatiramer acetate - Teva Pharmaceuticals

Drug Profile

Glatiramer acetate - Teva Pharmaceuticals

Alternative Names: COP-1; Copaxone; Copolymer-1

Latest Information Update: 18 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Weizmann Institute of Science
  • Developer Lundbeck A/S; Proneuron Biotechnologies; Takeda; Teva Neuroscience; Teva Pharmaceutical Industries
  • Class Peptides; Polymers
  • Mechanism of Action Immunomodulators; MHC class II gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple sclerosis
  • Discontinued Amyotrophic lateral sclerosis; Glaucoma; Huntington's disease; Neurological disorders

Most Recent Events

  • 11 Dec 2017 Teva Pharmaceuticals dismisses its pending district court litigation against Mylan regarding glatiramer acetate injection 40 mg/mL
  • 11 Dec 2017 Teva Pharmaceuticals withdraws litigation against Mylan regarding glatiramer acetate injection 40 mg/mL in Ireland
  • 26 Oct 2017 Teva Pharmaceuticals files patent infringement action against Mylan in Ireland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top